Odyssey Health, Inc.
For the period ended Oct 31, 2025. Filed Dec 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Oct 31, 2025 · Filed Dec 11, 2025
ODYYStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Three Months Ended October 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(483,447) | $(1,018,906) |
| Adjustments to reconcile net loss to net cash flows used in operating activities: | ||
| Stock-based compensation | – | 60,487 |
| Financing costs | 507,368 | – |
| Allowance for research and development rebate due | – | 22,625 |
| Change in fair value of derivative liability | (422,419) | – |
| Amortization of debt discount and closing costs | 39,601 | 19,801 |
| Loss from change in fair value of Oragenics, Inc. common stock | – | 370,698 |
| Financing costs paid with issuance of common stock | 1,750 | – |
| Changes in operating assets and liabilities: | ||
| Increase in prepaid expenses and other current assets | (87,397) | (96,736) |
| Increase in accounts payable and accrued wages | 73,285 | 181,743 |
| Increase in accounts payable and accrued wages, officers | 32,308 | 163,495 |
| Increase in accrued interest | 54,953 | 48,279 |
| Net cash used in operating activities | (283,998) | (248,514) |
| Cash flows from financing activities: | ||
| Net proceeds from notes payable | 290,500 | 300,000 |
| Net cash provided by financing activities | 290,500 | 300,000 |
| Net increase in cash and cash equivalents | 6,502 | 51,486 |
| Cash and cash equivalents: | ||
| Beginning of period | 19,084 | 2,379 |
| End of period | $25,586 | $53,865 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $783 | $705 |
| Supplemental disclosure of non-cash information: | ||
| Common stock issued for conversion of outstanding principal | $144,000 | $– |
| Common stock issued for conversion of accrued interest | 80,618 | – |
| Warrants issued in debt financing | 56,589 | 13,343 |
| Original issue discount on debt and closing costs on notes payable | 29,500 | – |
| Debt discount recognized on notes payable associated with derivative liability | 140,206 | – |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.